TRYVIO™ (aprocitentan) now included in ACC/AHA Clinical Practice Guidelines for the treatment of hypertension

Allschwil, Switzerland & Radnor, Pennsylvania – August 19, 2025 Idorsia Ltd (SIX: IDIA) announces that its novel dual endothelin receptor antagonist (ERA), TRYVIO™ (aprocitentan), has been included in the new comprehensive clinical practice guidelines for the management of systemic hypertension, published by the American College of Cardiology (ACC) and the American Heart Association (AHA) Joint Committee. The updated recommendations now list TRYVIO as a therapy that may be added for adults with difficult-to-control hypertension, including resistant hypertension. TRYVIO is the first systemic hypertension treatment to target a new pathway in over 30 years and the only new medicine to be included in the updated guidelines.